Cited by

• The future of cystic fibrosis care: a global perspective.

  Bell SC, Mall MA, Gutierrez H, Macek M, Madge S, Davies JC, Burgel PR, Tullis E, Castaños C, Castellani C, Byrnes CA, Cathcart F, Chotirmall SH, Cosgriff R, Eichler I, Fajac I, Goss CH, Drevinek P, Farrell PM, Gravelle AM, Havermans T, Mayer-Hamblett N, Kashirskaya N, Kerem E, Mathew JL, McKone EF, Naehrlich L, Nasr SZ, Oates GR, O'Neill C, Pypops U, Raraigh KS, Rowe SM, Southern KW, Sivam S, Stephenson AL, Zampoli M, Ratjen F. Bell SC, et al. Lancet Respir Med. 2020 Jan;8(1):65-124. doi: 10.1016/S2213-2600(19)30337-6. Epub 2019 Sep 27. Lancet Respir Med. 2020. PMID: 31570318 Free PMC article. Review.
• Why it's Time to Abandon the ICER.

  Paulden M. Paulden M. Pharmacoeconomics. 2020 Aug;38(8):781-784. doi: 10.1007/s40273-020-00915-5. Pharmacoeconomics. 2020. PMID: 32390066 No abstract available.
• A non-stationary Markov model for economic evaluation of grass pollen allergoid immunotherapy.

  Bilancia M, Pasculli G, Di Bona D. Bilancia M, et al. PLoS One. 2020 May 14;15(5):e0232753. doi: 10.1371/journal.pone.0232753. eCollection 2020. PLoS One. 2020. PMID: 32407326 Free PMC article.
• Considerations when applying equity weights within economic evaluation when making drug reimbursement decisions.

  Coyle D. Coyle D. Health Econ Rev. 2024 Nov 13;14(1):90. doi: 10.1186/s13561-024-00556-w. Health Econ Rev. 2024. PMID: 39532792 Free PMC article.
• Framework for developing cost-effectiveness analysis threshold: the case of Egypt.

  Fasseeh AN, Korra N, Elezbawy B, Sedrak AS, Gamal M, Eldessouki R, Eldebeiky M, George M, Seyam A, Abourawash A, Khalifa AY, Shaheen M, Abaza S, Kaló Z. Fasseeh AN, et al. J Egypt Public Health Assoc. 2024 Jun 3;99(1):12. doi: 10.1186/s42506-024-00159-7. J Egypt Public Health Assoc. 2024. PMID: 38825614 Free PMC article.